Deal Team

Corporate
Antitrust
Executive Compensation and Benefits
Restructuring and Finance
Tax

Becton Dickinson in its plan to pursue a separation of its Biosciences and Diagnostic Solutions business

On February 5, 2025, BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that its board of directors has unanimously authorized management to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD. The separation decision was the result of a comprehensive business portfolio evaluation launched by BD in early 2024.

Wachtell, Lipton, Rosen & Katz is serving as legal advisor to BD.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.